IL17A and inflammatory bowel disease: In addition, the increase in Parasutterella after IL-17A inhibitor therapy may be related to the development of inflammatory bowel disease in some PSO patients (97), as higher levels of Parasutterella are associated with chronic inflammation in Irritable Bowel Syndrome (IBS) (98).